Recent

% | $
Quotes you view appear here for quick access.

ЕЛН Message Board

  • wendell3308 wendell3308 Oct 28, 2008 11:42 AM Flag

    BAP Alzheimer's Clinical Trial Full! - APOE4 Carriers!

    Big money has gotten their loved ones into this clinical trial for bapineuzumab.
    Elan scientists are using the lower dose level which showed NO vasogenic edema problems.

    Probably also using a dosing regimen that will eliminate the RISK and allow only the BENEFITS.

    Six months from now, there will be a rumbling in the medical community as it'll be known that bapineuzumab does stop the amyloid cascade with Alzheimer's.

    While the APOE4 non-carrier clinical trials are still recruiting, there are ONLY a few slots left....
    ...so it's probably too late to get your loved one into it.

    Here's the link to the bapineuzumab clinical trial that completed it's enrollment....

    http://www.clinicaltrials.gov/ct2/show/NCT00575055?term=bapineuzumab&rank=4

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That's fucking great but what about all of the fucking money I've lost on the POS........

    • Thanks for the link.I don't see mention of the study being full?

      • 1 Reply to grbnitz2004
      • The NIH/FDA does not announce that the trials are full....

        Instead they prefer to use the words...

        "This study is ongoing, but not recruiting participants."

        from the link,
        http://www.clinicaltrials.gov/ct2/show/NCT00575055?term=bapineuzumab&rank=4

        Now I'll walk you through the logic of why this clinical trial is "FULL".

        Prior to posting "This study is ongoing, but no recruiting participants.", the NIH/FDA has the clinical trial post....

        "This study is currently recruiting participants."

        An example of this can be found at the link below for the remaining bapineuzumab Phase III clinical trial for non-APOE4 carriers,

        http://www.clinicaltrials.gov/ct2/show/NCT00574132?term=Elan+Alzheimer%27s&rank=4

        Now if you go to another link that shows all of Elan's clinical trials for Alzheimer's, you'll see that a list of clinical trials is presented, some which say, "Recruiting" others say "Active, not recruiting" and still others say "Terminated"....

        here's the link,
        http://www.clinicaltrials.gov/ct2/results?term=Elan+Alzheimer%27s

        Now one must deduce that if the clinical trial is "Active", it means that there are participants in the trial. Similarly, if the clinical trial is "Active, but not recruiting", one can deduce that the clinical trial is FULL.

        Hope this helps. Here's the listing of Elan's Alzheimer's clinical trials there are 8 shown, but only 3 are recruiting & 1 hasn't started yet in Japan....

        1 Recruiting ELND005 in Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer Disease
        Interventions: Drug: ELND005; Drug: Placebo Control; Drug: ELND005; Drug: ELND005
        Phase: Phase II

        2 Active, not recruiting AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer's Disease
        Intervention: Drug: AAB-001
        Phase: Phase II

        3 Active, not recruiting Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer's Disease
        Interventions: Drug: Bapineuzumab; Drug: Placebo Control
        Phase: Phase III

        4 Recruiting Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer's Disease
        Interventions: Drug: Bapineuzumab; Drug: Placebo Control; Drug: Bapineuzumab; Drug: Bapineuzumab
        Phase: Phase III

        5 Active, not recruiting AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer's Disease
        Interventions: Drug: Bapineuzumab (AAB-001); Drug: Bapineuzumab (AAB-001); Drug: Bapineuzumab (AAB-001); Drug: Bapineuzumab (AAB-001)
        Phase: Phase II

        6 Terminated Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease
        Condition: Alzheimer's Disease
        Intervention: Biological: AN-1792 also known as AIP-001
        Phase: Phase II

        7 Recruiting Study Evaluating Safety, Tolerability, and Immunogenicity of ACC-001 in Subjects With Alzheimer's Disease
        Condition: Alzheimer Disease
        Interventions: Biological: ACC-001 + QS-21; Biological: ACC-001; Biological: QS-21; Drug: Phosphate buffered saline
        Phase: Phase II

        8 Not yet recruiting Study Evaluating ACC-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease
        Condition: Alzheimer Disease
        Interventions: Biological: ACC-001; Biological: QS-21
        Phase: Phase II

 
ELN
0.0000(0.00%)